Literature DB >> 31160102

Evaluating the effectiveness of the influenza vaccine during respiratory outbreaks in Singapore's long term care facilities, 2017.

Yixiang Ng1, Khine Nandar2, Lily Ai Vee Chua3, Tze Minn Mak4, Kelly Foo2, Imran Roshan Muhammad2, Constance Khia Ki Low2, Stefan Ma3, Steven Peng-Lim Ooi2, Raymond Tzer Pin Lin4, Lyn James3, Vernon Jian Ming Lee2.   

Abstract

Influenza outbreaks occur periodically in Long Term Care Facilities (LTCFs) and vaccination is critical in preventing influenza infections. We evaluated the influenza vaccine effectiveness (VE) during respiratory outbreaks in LTCFs reported to the Ministry of Health, Singapore in 2017. A test-negative design was used to estimate the ratio of the odds of testing positive for influenza among vaccinated individuals to the odds among unvaccinated individuals. The VE was calculated as (1-odds ratio) × 100%. For adjusted VE, the estimates were derived using logistic regression adjusted for age group, gender, month of illness, and number of days from date of illness onset till to swab collection date. Estimates by influenza subtypes and post-vaccination time periods (15-180 days & 181-365 days) were also calculated using stratified data. 264 individuals, with 118 laboratory-confirmed influenza cases [32 A(H1N1)pdm09, 75 A(H3N2), 11 A(untypable)], were included in the analysis. No one was identified to be infected with influenza B. The overall adjusted VE estimate was 40.5% (95% CI: -12.2-68.5%), while the subtype-specific adjusted VE estimates were -43.4% (95% CI: -312.4-50.2%) against A(H1N1)pdm09 and 57.1% (95% CI: 5.7-80.5%) against A(H3N2). At 15-180 days post-vaccination period, the adjusted VEs were 59.3% (95% CI: 18.0-79.8%) against all influenza, 35.4% (95% CI: -123.5-81.3%) against A(H1N1)pdm09 and 67.9% (95% CI: 22.5-86.7%) against A(H3N2). Estimates were not significant at 181-365 days post-vaccination. The influenza vaccine showed varying effectiveness among individuals in Singapore's LTCFs in 2017, with a higher effectiveness among those who were more recently vaccinated. It remains an important tool in preventing influenza infections, especially for those who are at high risk of influenza-related complications.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2017; Effectiveness; Influenza vaccine; Outbreak investigation; Test-negative design; Tropics

Year:  2019        PMID: 31160102     DOI: 10.1016/j.vaccine.2019.03.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Estimates of influenza-associated hospitalisations in tropical Singapore, 2010-2017: Higher burden estimated in more recent years.

Authors:  Yixiang Ng; Lily Ai Vee Chua; Stefan Ma; Vernon Jian Ming Lee
Journal:  Influenza Other Respir Viruses       Date:  2019-08-21       Impact factor: 4.380

2.  Influenza in temperate and tropical Asia: a review of epidemiology and vaccinology.

Authors:  Barnaby Edward Young; M Chen
Journal:  Hum Vaccin Immunother       Date:  2020-02-04       Impact factor: 3.452

3.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.

Authors:  Lisa A Grohskopf; Lenee H Blanton; Jill M Ferdinands; Jessie R Chung; Karen R Broder; H Keipp Talbot; Rebecca L Morgan; Alicia M Fry
Journal:  MMWR Recomm Rep       Date:  2022-08-26

Review 4.  Subtype H3N2 Influenza A Viruses: An Unmet Challenge in the Western Pacific.

Authors:  Min Kang; Mark Zanin; Sook-San Wong
Journal:  Vaccines (Basel)       Date:  2022-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.